Anaphylm

Aquestive Therapeutics ($AQST) investors have until May 4, 2026 to join a securities fraud lawsuit alleging the company concealed human factors issues with its Anaphylm sublingual film product.

Class action lawsuit filed against Aquestive Therapeutics after company failed to disclose FDA deficiencies blocking Anaphylm approval, triggering 37% stock decline.

Class action lawsuit filed against $AQST alleging securities fraud over false FDA timeline statements and concealed safety risks for Anaphylm drug.

Class action lawsuit filed against $AQST alleging executives made false statements about Anaphylm FDA approval timeline and concealed human factors risks.

Rosen Law Firm alerts AQST investors of May 4, 2026 deadline to join class action alleging Aquestive Therapeutics concealed human factors issues with its Anaphylm drug application.

Aquestive Therapeutics faces securities lawsuit after FDA Anaphylm deficiency notice triggers 37% stock decline from $6.21 to $3.91 on January 9, 2026.

Aquestive Therapeutics faces class action lawsuit alleging securities fraud over false FDA approval statements and concealed anaphylaxis product risks.

Aquestive Therapeutics faces class action lawsuit alleging FDA approval misrepresentations for Anaphylm. Stock dropped 37% January 9; lead plaintiff applications due May 4, 2026.

Aquestive Therapeutics faces securities fraud lawsuit after 37% stock drop tied to undisclosed FDA deficiencies in Anaphylm NDA. Lead plaintiff recruitment deadline: May 4, 2026.

Class action lawsuit filed against Aquestive Therapeutics alleging securities fraud related to Anaphylm FDA approval timeline and undisclosed human factors risks.

Portnoy Law Firm files class action against Aquestive Therapeutics for allegedly failing to disclose FDA deficiencies in Anaphylm NDA, causing 37% stock decline.

Aquestive Therapeutics faces securities fraud lawsuit after FDA rejected Anaphylm drug, contradicting management's prior "on track" statements; $AQST stock fell 37%.

Rosen Law Firm seeks lead plaintiffs in securities lawsuit against Aquestive Therapeutics over alleged false statements regarding Anaphylm drug application.

Aquestive Therapeutics appoints Day Pitney partner Thomas Zalewski as Chief Legal Officer and Chief Compliance Officer, with Lori Braender transitioning to Corporate Secretary after eight years.

$AQST plummets 37% after FDA rejects Anaphylm application. Investors sue over alleged misleading statements about approval prospects.

Class action lawsuit filed against $AQST alleging misleading statements about FDA approval timeline for Anaphylm and concealed human factors risks.

Aquestive Therapeutics faces securities class action over alleged false FDA approval statements for Anaphylm drug. Stock fell 37% after January 2026 NDA rejection.

Rosen Law Firm files securities class action against $AQST over alleged misleading statements regarding its Anaphylm drug application between June 2025 and January 2026.

Aquestive Therapeutics will present at four major healthcare investor conferences in March 2026, updating investors on its clinical pipeline and strategic initiatives.

Aquestive Therapeutics will report Q4 2025 results March 4 and hold investor call March 5, discussing financial performance and pipeline progress including Anaphylm™ development.